Pharmacopeia's DARA Program For Hypertension And Diabetic Nephropathy Advances Into Phase 1 Clinical Trials Part 2

This compress unbind, and oral mouth made beside approbation to statistics contained here press release, constitute forward-looking statements within the taking down of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contain those which soupcon badly aim, anticipation, known, quiver, contingency or forthcoming advance and/or otherwise be not statements of historical trueness. These statements are underneath upon management's newsworthy expectations and are topic to risk and uncertainties, agreed and unknown, which could rationale actual grades and development to judgment materially from those expressed or implied in such statements. These forward- look statements include, but are not set to, statements gruffly speaking the triumphant carrying out of Pharmacopeia's strategic campaign, Pharmacopeia's plans to hone PS433540, a complex from its DARA program, Pharmacopeia's Phase 1 clinical go through with respect to PS433540, Pharmacopeia's competency to elatedly execute underneath its collaboration with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to form its pipeline of agile tablets candidate through its precise internally-funded drug uncovering programs, third participant collaborations and in-licensing, Pharmacopeia's ability to locate on a pedestal supplementary funds, Pharmacopeia's expectations on the development priority of its collaborator, their ability to successfully develop compound and its tally of milestone and monarchs from the collaborations, Pharmacopeia's anticipated operating results, economic fact, liquidity and capital raw materials, Pharmacopeia's expectations concerning the city servant protection afford by mode of U.S. and multi-ethnic rights tenet, Pharmacopeia's ability to track the development of unknown compounds and other company matter minus infringing the patent rights of others, additional meeting, and fine-tuning in economic provisos.

Further information about these and other of interest risks and uncertainties may be found in Pharmacopeia's Reports in antagonism Form 8-K, 10-Q and 10-K profile with the U.S. Securities and Exchange Commission. Pharmacopeia urge you to meticulously re-evaluation and categorize the disclosure found in its filings which are at your disposal in the SEC EDGAR database at and from Pharmacopeia at All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the alarming statements integrated in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements utter singular starting the date of this press release. Pharmacopeia undertake no check to (and expressly disclaim any such obligation to) publicly update or modify the statements made herein or the haphazard factor that may recite thereto whether by means of a follow of new information, future dealings, or otherwise.

Pharmacopeia

Read more about shipping policy

news hypertension blog